These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36951259)

  • 21. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
    Vidriales MB; Pérez-López E; Pegenaute C; Castellanos M; Pérez JJ; Chandía M; Díaz-Mediavilla J; Rayón C; de Las Heras N; Fernández-Abellán P; Cabezudo M; de Coca AG; Alonso JM; Olivier C; Hernández-Rivas JM; Montesinos P; Fernández R; García-Suárez J; García M; Sayas MJ; Paiva B; González M; Orfao A; San Miguel JF;
    Leuk Res; 2016 Jan; 40():1-9. PubMed ID: 26598032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
    den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
    Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetics of paediatric acute myeloid leukaemia.
    Jones L; McCarthy P; Bond J
    Br J Haematol; 2020 Jan; 188(1):63-76. PubMed ID: 31804725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia.
    Xia L; Guo H; Wu X; Xu Y; Zhao P; Yan B; Zeng Y; He Y; Chen D; Gale RP; Zhang Y; Zhang X
    Theranostics; 2023; 13(4):1289-1301. PubMed ID: 36923527
    [No Abstract]   [Full Text] [Related]  

  • 25. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
    Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins.
    Wang Y; Chen S; Chi P; Nie R; Gale RP; Huang H; Chen Z; Cai Y; Yan E; Zhang X; Zhong N; Liang Y
    Br J Haematol; 2022 Nov; 199(4):572-586. PubMed ID: 36113865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of a murine leukaemia stem cell gene signature based on nucleostemin promoter activity with prognosis of acute myeloid leukaemia in patients.
    Ali MA; Naka K; Yoshida A; Fuse K; Kasada A; Hoshii T; Tadokoro Y; Ueno M; Ohta K; Kobayashi M; Takahashi C; Hirao A
    Biochem Biophys Res Commun; 2014 Jul; 450(1):837-43. PubMed ID: 24960197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA profiling of paediatric AML with
    Leoncini PP; Vitullo P; Reddel S; Tocco V; Paganelli V; Stocchi F; Mariggiò E; Massa M; Nigita G; Veneziano D; Fadda P; Scarpa M; Pigazzi M; Bertaina A; Rota R; Pagliara D; Merli P
    Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36321792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of three miRNA signatures with prognostic value in non-M3 acute myeloid leukemia.
    Xue Y; Ge Y; Kang M; Wu C; Wang Y; Rong L; Fang Y
    BMC Cancer; 2019 Jan; 19(1):109. PubMed ID: 30700251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Applying molecular measurable residual disease testing in acute myeloid leukaemia.
    Krigstein M; Iland HJ; Wei AH
    Pathology; 2023 Feb; 55(1):1-7. PubMed ID: 36503638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.
    Liersch R; Müller-Tidow C; Berdel WE; Krug U
    Br J Haematol; 2014 Apr; 165(1):17-38. PubMed ID: 24484469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular markers in acute myeloid leukaemia.
    Kühnl A; Grimwade D
    Int J Hematol; 2012 Aug; 96(2):153-63. PubMed ID: 22791509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytogenetic Abnormalities and Their Impact on Treatment Outcome in Paediatric Acute Myeloid Leukaemia in Pakistan.
    Khalil S; Ghafoor T; Farah T; Arshad A
    J Coll Physicians Surg Pak; 2020 Apr; 30(4):379-384. PubMed ID: 32513356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-638 in circulating leukaemia cells as a non-invasive biomarker in diagnosis, treatment response and MRD surveillance of acute promyelocytic leukaemia.
    Bai Y; Chen C; Guo X; Ding T; Yang X; Yu J; Yang J; Ruan J; Zheng X; Chen Z
    Cancer Biomark; 2020; 29(1):125-137. PubMed ID: 32568176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.
    Trino S; Lamorte D; Caivano A; Laurenzana I; Tagliaferri D; Falco G; Del Vecchio L; Musto P; De Luca L
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29401684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Shiba N; Ohki K; Kobayashi T; Hara Y; Yamato G; Tanoshima R; Ichikawa H; Tomizawa D; Park MJ; Shimada A; Sotomatsu M; Arakawa H; Horibe K; Adachi S; Taga T; Tawa A; Hayashi Y
    Br J Haematol; 2016 Feb; 172(4):581-91. PubMed ID: 26684393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia.
    Weng H; Lal K; Yang FF; Chen J
    Cancer Genet; 2015 May; 208(5):225-9. PubMed ID: 25686674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.